Investment Analysts’ Recent Ratings Changes for Hinge Health (HNGE)

Several analysts have recently updated their ratings and price targets for Hinge Health (NYSE: HNGE):

• 6/17/2026 – Hinge Health had its price target raised by Robert W. Baird from $55.00 to $65.00. They now have a “neutral” rating on the stock.
• 6/15/2026 – Hinge Health had its price target raised by Raymond James Financial, Inc. from $70.00 to $80.00. They now have an “outperform” rating on the stock.
• 6/15/2026 – Hinge Health had its price target raised by Canaccord Genuity Group Inc. from $65.00 to $76.00. They now have a “buy” rating on the stock.
• 6/12/2026 – Hinge Health had its price target raised by KeyCorp from $75.00 to $90.00. They now have an “overweight” rating on the stock.
• 6/11/2026 – Hinge Health had its price target raised by Barclays PLC from $62.00 to $70.00. They now have an “overweight” rating on the stock.
• 6/11/2026 – Hinge Health had its price target raised by Royal Bank Of Canada from $65.00 to $75.00. They now have an “outperform” rating on the stock.
• 6/11/2026 – Hinge Health had its price target raised by Truist Financial Corporation from $79.00 to $85.00. They now have a “buy” rating on the stock.
• 6/11/2026 – Hinge Health had its price target raised by Needham & Company LLC from $63.00 to $76.00. They now have a “buy” rating on the stock.
• 6/10/2026 – Hinge Health had its “overweight” rating reaffirmed by Piper Sandler.
• 6/10/2026 – Hinge Health was given a new $79.00 price target by Stifel Nicolaus.
• 6/6/2026 – Hinge Health was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 6/4/2026 – Hinge Health had its price target raised by Canaccord Genuity Group Inc. from $63.00 to $65.00. They now have a “buy” rating on the stock.
• 5/23/2026 – Hinge Health was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 5/13/2026 – Hinge Health was upgraded by Zacks Research from “hold” to “strong-buy”.
• 5/10/2026 – Hinge Health was upgraded by Wall Street Zen from “hold” to “buy”.
• 5/6/2026 – Hinge Health was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 5/6/2026 – Hinge Health was given a new $79.00 price target by Truist Financial Corporation.
• 5/6/2026 – Hinge Health had its “outperform” rating reaffirmed by Raymond James Financial, Inc.. They now have a $70.00 price target on the stock.
• 5/6/2026 – Hinge Health had its “overweight” rating reaffirmed by Piper Sandler. They now have a $95.00 price target on the stock.
• 5/6/2026 – Hinge Health had its price target raised by Royal Bank Of Canada from $55.00 to $65.00. They now have an “outperform” rating on the stock.
• 5/6/2026 – Hinge Health had its price target raised by Canaccord Genuity Group Inc. from $53.00 to $63.00. They now have a “buy” rating on the stock.
• 5/6/2026 – Hinge Health had its “outperform” rating reaffirmed by Citigroup Inc..
• 5/6/2026 – Hinge Health had its price target raised by Barclays PLC from $52.00 to $62.00. They now have an “overweight” rating on the stock.
• 5/6/2026 – Hinge Health had its price target raised by Stifel Nicolaus from $59.00 to $67.00. They now have a “buy” rating on the stock.
• 5/6/2026 – Hinge Health had its price target raised by Citizens Jmp from $65.00 to $80.00. They now have a “market outperform” rating on the stock.
• 5/6/2026 – Hinge Health had its price target raised by Wells Fargo & Company from $68.00 to $80.00. They now have an “overweight” rating on the stock.
• 5/6/2026 – Hinge Health had its price target raised by Needham & Company LLC from $59.00 to $63.00. They now have a “buy” rating on the stock.
• 5/2/2026 – Hinge Health was downgraded by Wall Street Zen from “buy” to “hold”.

Insider Activity at Hinge Health

In other news, CFO James Budge sold 5,907 shares of the company’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $53.79, for a total value of $317,737.53. Following the sale, the chief financial officer owned 445,386 shares in the company, valued at approximately $23,957,312.94. This represents a 1.31% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President James Pursley sold 16,000 shares of the company’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $53.79, for a total transaction of $860,640.00. Following the completion of the sale, the president owned 780,223 shares in the company, valued at approximately $41,968,195.17. This trade represents a 2.01% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 554,600 shares of company stock worth $29,859,068. Company insiders own 18.92% of the company’s stock.

Hinge Health (NYSE: HNGE) is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company’s platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions.

Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs.